<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pulmonary diseases associated with immunomodulatory agents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pulmonary diseases associated with immunomodulatory agents</h1>
<div class="graphic"><div class="figure"><div class="ttl">Pulmonary diseases associated with immunomodulatory agents</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="12%"></colgroup><colgroup width="76%"></colgroup> <tbody> <tr> <td class="subtitle1_left">Drug class</td> <td class="subtitle1_left">Drug</td> <td class="subtitle1_left">Complications</td> </tr> <tr class="divider_top"> <td class="divider_bottom" rowspan="34"><strong>TNF-alpha inhibitors</strong></td> <td class="divider_bottom" rowspan="10"><strong>Etanercept</strong></td> <td><strong>Infectious</strong></td> </tr> <tr> <td class="indent1"><em>Streptococcus pneumoniae</em></td> </tr> <tr> <td class="indent1">Histoplasmosis</td> </tr> <tr class="divider_bottom"> <td class="indent1">Tuberculosis</td> </tr> <tr> <td><strong>Noninfectious</strong></td> </tr> <tr> <td class="indent1">Systemic lupus erythematosus pleural disease</td> </tr> <tr> <td class="indent1">Pulmonary fibrosis</td> </tr> <tr> <td class="indent1">Granulomatous inflammation</td> </tr> <tr> <td class="indent1">Pneumonitis</td> </tr> <tr class="divider_bottom"> <td class="indent1">Exacerbation of interstitial disease</td> </tr> <tr> <td class="divider_bottom" rowspan="19"><strong>Infliximab</strong></td> <td><strong>Infectious</strong></td> </tr> <tr> <td class="indent1">Tuberculosis</td> </tr> <tr> <td class="indent1">Bovine tuberculosis</td> </tr> <tr> <td class="indent1">Cryptococcosis</td> </tr> <tr> <td class="indent1">Histoplasmosis</td> </tr> <tr> <td class="indent1">Legionellosis</td> </tr> <tr> <td class="indent1">Invasive and allergic aspergillosis</td> </tr> <tr> <td class="indent1"><em>Scedosporium</em> infection</td> </tr> <tr> <td class="indent1">Actinomycosis</td> </tr> <tr> <td class="indent1"><em>Pneumocystis jirovecii</em></td> </tr> <tr class="divider_bottom"> <td class="indent1">Coccidioidomycosis</td> </tr> <tr> <td><strong>Noninfectious</strong></td> </tr> <tr> <td class="indent1">Langerhans cell histiocytosis</td> </tr> <tr> <td class="indent1">Drug-induced alveolitis</td> </tr> <tr> <td class="indent1">Systemic lupus erythematosus pleural or parenchymal disease</td> </tr> <tr> <td class="indent1">Sarcoidosis</td> </tr> <tr> <td class="indent1">Interstitial pneumonitis</td> </tr> <tr> <td class="indent1">Diffuse alveolar hemorrhage</td> </tr> <tr class="divider_bottom"> <td class="indent1">Fibrosing alveolitis</td> </tr> <tr> <td class="divider_bottom" rowspan="5"><strong>Adalimumab</strong></td> <td><strong>Infectious</strong></td> </tr> <tr> <td class="indent1">Tuberculosis</td> </tr> <tr class="divider_bottom"> <td class="indent1">Aspergillosis</td> </tr> <tr> <td><strong>Noninfectious</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1">Pulmonary fibrosis</td> </tr> <tr> <td class="divider_bottom" rowspan="2"><strong>IL-1 inhibitor</strong></td> <td class="divider_bottom" rowspan="2"><strong>Anakinra</strong></td> <td><strong>Infectious</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1">Tuberculosis</td> </tr> <tr> <td class="divider_bottom" rowspan="2"><strong>Costimulation blockade</strong></td> <td class="divider_bottom" rowspan="2"><strong>Abatacept</strong></td> <td><strong>Infectious</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1">Bacterial pneumonia</td> </tr> <tr> <td rowspan="3"><strong>B-cell depletion</strong></td> <td rowspan="3"><strong>Rituximab</strong></td> <td><strong>Noninfectious</strong></td> </tr> <tr> <td class="indent1">Interstitial pneumonitis</td> </tr> <tr> <td class="indent1">Pulmonary fibrosis</td> </tr> </tbody></table></div><div class="graphic_footnotes">TNF-alpha: tumor necrosis factor-alpha; IL-1: interleukin-1.</div><div class="graphic_reference">Data from:

<ol>
<li>Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor alpha therapy. Am J Respir Crit Care Med 2003; 167:1279. </li>
<li>Abunasser J, Forouhar FA, Metersky ML. Etanercept-induced lupus erythematosis presenting as a unilateral pleural effusion. Chest 2008; 134:850. </li>
<li>Judson MA. Allergic bronchopulmonary aspergillosis after infliximab therapy for sarcoidosis: a potential mechanism related to T-helper cell cytokine balance. Chest 2009; 135:1358. </li>
<li>Larsen MV, Sorensen IJ, Thomsen VO, Ravn P. Re-activation of bovine tuberculosis in a patient treated with infliximab. Eur Respir J 2008; 32:229. </li>
<li>Dweik M, Baethge BA, Duarte AG. Coccidioidomycosis pneumonia in a nonendemic area associated with infliximab. South Med J 2007; 100:517. </li>
<li>O'Shea FD, Marras TK, Inman RD. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum 2006; 55:978. </li>
<li>Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol 2006; 33:1189. </li>
<li>Hage CA, Wood KL, Winer-Muram HT, et al. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 2003; 124:2395. </li>
<li>De Rosa FG, Shaz D, Campagna AC, et al. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol 2003; 24:477. </li>
<li>Allanore Y, Devos Francosis G, Caramella C, et al. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 2006; 65:834. </li>
<li>Bitzan M, Anselmo M, Carpineta L. Rituximab (B-cell depleting antibody) associated with lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonal 2009; 44:922. </li>
<li>Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007; 82:916. </li>
<li>Biehn SE, Kirk D, Rivera MP, et al. Bronchioltis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkins lymphoma. Hematol Oncol 2006; 24:234. </li>
<li>Kuru T, Lynch LP 3rd. Nonresolving or slowly resolving pneumonia. Clin Chest Med 1999; 20:623. </li>
</ol></div><div id="graphicVersion">Graphic 69809 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
